Kymera Therapeutics, Inc. (NASDAQ: KYMR) has seen significant insider activity following a period of intense market performance. According to recent filings submitted to the Securities and Exchange Commission, Chief Executive Officer Nello Mainolfi sold common stock totaling roughly $2,435,377 on April 29, 2026.
The transaction involved the sale of 30,000 shares of common stock. These sales were preceded by the exercise of an equivalent number of stock options, which were fully vested and exercisable at an exercise price of $2.08 per share. The total liquidation was carried out through several distinct tranches of transactions, each with varying weighted average prices:
- First Tranche: 17,005 shares were sold at a weighted average price of $80.74. Individual prices within this group ranged from $80.23 to $81.215.
- Second Tranche: 12,059 shares were sold at a weighted average price of $81.70. The specific transaction prices for these shares fluctuated between $81.23 and $82.18.
- Third Tranche: 936 shares were sold at a weighted average price of $82.45, with individual sale prices spanning from $82.30 to $83.07.
The overall weighted average price for the entire block of stock sold ranged between $80.74 and $82.45 per share. This selling activity took place against a backdrop of significant upward momentum for Kymera shares, which have surged nearly 149% over the past year. Despite this growth, analysis from InvestingPro suggests that the stock may currently be overvalued relative to its calculated Fair Value. The company maintains a market capitalization of $6.69 billion.
Following the completion of these trades, Mr. Mainolfi retains a direct holding of 666,195 shares of Kymera Therapeutics common stock. Furthermore, he holds 215,559 derivative securities in the form of stock options, which are set to expire on November 13, 2029.
While the insider sale draws attention to valuation metrics, Kymera Therapeutics continues to advance its clinical and strategic objectives within the biotechnology sector. The U.S. Food and Drug Administration has granted Fast Track designation to KT-621, a candidate designed for the treatment of moderate to severe eosinophilic asthma. The company is currently managing Phase 2b studies for KT-621 in the context of both atopic dermatitis and asthma.
Strategic partnerships also remain a component of the company's current landscape. Gilead Sciences has opted to exercise its rights to license Kymera's CDK2 degrader, known as KT-200. This licensing agreement has resulted in a milestone payment of $45 million to Kymera, with Gilead moving forward to advance KT-200 into subsequent studies.
Market analysts have also provided varying perspectives on the company's trajectory. H.C. Wainwright recently maintained a buy rating for Kymera Therapeutics with a price target of $134, following discussions regarding the firm's ongoing clinical trials. In contrast, Stephens adjusted its price target for the stock to $100, citing recent financial updates and the company's pipeline. Looking ahead, Kymera is scheduled to present data from its KT-621 trial for atopic dermatitis at the American Academy of Dermatology meeting in 2026.